Hypothalamic: Pituitary Dysfunction as a Late Effect of Childhood Cancer, Brain Tumors, and Their Treatments

  • Wassim ChemaitillyEmail author
Part of the Contemporary Endocrinology book series (COE)


Hypothalamic pituitary (HP) dysfunction is frequently observed in survivors of childhood cancer and brain tumors. The main risk factors are tumor growth and/or surgery or radiotherapy involving the HP region. Radiation-induced HP dysfunction most frequently occurs as a late effect, months to years after the completion of cancer/tumor therapy. Systematic assessments where CCS are periodically screened based on their cancer/tumor treatment history allow the early diagnosis and treatment of this condition and can potentially ameliorate long-term health outcomes.


Childhood cancer survivor Endocrine late effects Endocrine complications Radiotherapy late effects Chemotherapy late effects 


  1. 1.
    Ward E, DeSantis C, Robbins A, Kohler B, Jemal A. Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin. 2014;64(2):83–103.PubMedGoogle Scholar
  2. 2.
    Diller L, Chow EJ, Gurney JG, Hudson MM, Kadin-Lottick NS, Kawashima TI, et al. Chronic disease in the childhood cancer survivor study cohort: a review of published findings. J Clin Oncol. 2009;27(14):2339–55.PubMedPubMedCentralGoogle Scholar
  3. 3.
    Hudson MM, Ness KK, Gurney JG, Mulrooney DA, Chemaitilly W, Krull KR, et al. Clinical ascertainment of health outcomes among adults treated for childhood cancer. JAMA. 2013;309(22):2371–81.PubMedPubMedCentralGoogle Scholar
  4. 4.
    Chemaitilly W, Li Z, Huang S, Ness KK, Clark KL, Green DM, et al. Anterior hypopituitarism in adult survivors of childhood cancers treated with cranial radiotherapy: a report from the st jude lifetime cohort study. J Clin Oncol. 2015;33(5):492–500.PubMedPubMedCentralGoogle Scholar
  5. 5.
    Brignardello E, Felicetti F, Castiglione A, Chiabotto P, Corrias A, Fagioli F, et al. Endocrine health conditions in adult survivors of childhood cancer: the need for specialized adult-focused follow-up clinics. Eur J Endocrinol. 2013;168(3):465–72.PubMedGoogle Scholar
  6. 6.
    Clement SC, Schouten-van Meeteren AY, Boot AM, Claahsen-van der Grinten HL, Granzen B, Sen Han K, et al. Prevalence and risk factors of early endocrine disorders in childhood brain tumor survivors: a nationwide, multicenter study. J Clin Oncol. 2016;34(36):4362–70.PubMedGoogle Scholar
  7. 7.
    Chemaitilly W, Armstrong GT, Gajjar A, Hudson MM. Hypothalamic-pituitary axis dysfunction in survivors of childhood CNS tumors: importance of systematic follow-up and early endocrine consultation. J Clin Oncol. 2016;34(36):4315–9.PubMedGoogle Scholar
  8. 8.
    Laughton SJ, Merchant TE, Sklar CA, Kun LE, Fouladi M, Broniscer A, et al. Endocrine outcomes for children with embryonal brain tumors after risk-adapted craniospinal and conformal primary-site irradiation and high-dose chemotherapy with stem-cell rescue on the SJMB-96 trial. J Clin Oncol. 2008;26(7):1112–8.PubMedGoogle Scholar
  9. 9.
    Eaton BR, Esiashvili N, Kim S, Patterson B, Weyman EA, Thornton LT, et al. Endocrine outcomes with proton and photon radiotherapy for standard risk medulloblastoma. Neuro Oncol. 2015;18:881–7.PubMedPubMedCentralGoogle Scholar
  10. 10.
    Viswanathan V, Pradhan KR, Eugster EA. Pituitary hormone dysfunction after proton beam radiation therapy in children with brain tumors. Endocr Pract. 2011;17(6):891–6.PubMedPubMedCentralGoogle Scholar
  11. 11.
    Bishop AJ, Greenfield B, Mahajan A, Paulino AC, Okcu MF, Allen PK, et al. Proton beam therapy versus conformal photon radiation therapy for childhood craniopharyngioma: multi-institutional analysis of outcomes, cyst dynamics, and toxicity. Int J Radiat Oncol Biol Phys. 2014;90(2):354–61.PubMedPubMedCentralGoogle Scholar
  12. 12.
    Rose SR, Schreiber RE, Kearney NS, Lustig RH, Danish RK, Burghen GA, et al. Hypothalamic dysfunction after chemotherapy. J Pediatr Endocrinol Metab. 2004;17(1):55–66.PubMedGoogle Scholar
  13. 13.
    Gurney JG, Ness KK, Sibley SD, O’Leary M, Dengel DR, Lee JM, et al. Metabolic syndrome and growth hormone deficiency in adult survivors of childhood acute lymphoblastic leukemia. Cancer. 2006;107(6):1303–12.PubMedGoogle Scholar
  14. 14.
    Bakker B, Oostdijk W, Bresters D, Walenkamp MJ, Vossen JM, Wit JM. Disturbances of growth and endocrine function after busulphan-based conditioning for haematopoietic stem cell transplantation during infancy and childhood. Bone Marrow Transplant. 2004;33(10):1049–56.PubMedGoogle Scholar
  15. 15.
    Lodish MB. Clinical review: kinase inhibitors: adverse effects related to the endocrine system. J Clin Endocrinol Metab. 2013;98(4):1333–42.PubMedPubMedCentralGoogle Scholar
  16. 16.
    Rastogi MV, Stork L, Druker B, Blasdel C, Nguyen T, Boston BA. Imatinib mesylate causes growth deceleration in pediatric patients with chronic myelogenous leukemia. Pediatr Blood Cancer. 2012;59(5):840–5.PubMedGoogle Scholar
  17. 17.
    Corsello SM, Barnabei A, Marchetti P, De VL, Salvatori R, Torino F. Endocrine side effects induced by immune checkpoint inhibitors. J Clin Endocrinol Metab. 2013;98(4):1361–75.PubMedGoogle Scholar
  18. 18.
    Torino F, Barnabei A, Paragliola RM, Marchetti P, Salvatori R, Corsello SM. Endocrine side-effects of anti-cancer drugs: mAbs and pituitary dysfunction: clinical evidence and pathogenic hypotheses. Eur J Endocrinol. 2013;169(6):R153–R64.PubMedGoogle Scholar
  19. 19.
    Chemaitilly W, Cohen L. Diagnosis of endocrine disease: endocrine late effects of childhood cancer and its treatments. Eur J Endocrinol. 2017;176:R183–203.PubMedGoogle Scholar
  20. 20.
    Mostoufi-Moab S, Seidel K, Leisenring WM, Armstrong GT, Oeffinger KC, Stovall M, et al. Endocrine abnormalities in aging survivors of childhood cancer: a report from the childhood cancer survivor study. J Clin Oncol. 2016;34:3240.PubMedPubMedCentralGoogle Scholar
  21. 21.
    Merchant TE, Rose SR, Bosley C, Wu S, Xiong X, Lustig RH. Growth hormone secretion after conformal radiation therapy in pediatric patients with localized brain tumors. J Clin Oncol. 2011;29(36):4776–80.PubMedPubMedCentralGoogle Scholar
  22. 22.
    Pui CH, Evans WE. A 50-year journey to cure childhood acute lymphoblastic leukemia. Semin Hematol. 2013;50(3):185–96.PubMedPubMedCentralGoogle Scholar
  23. 23.
    Wilson CL, Chemaitilly W, Jones KE, Kaste SC, Srivastava DK, Ojha RP, et al. Modifiable factors associated with aging phenotypes among adult survivors of childhood acute lymphoblastic leukemia. J Clin Oncol. 2016;34(21):2509–15.PubMedPubMedCentralGoogle Scholar
  24. 24.
    Brauner R, Czernichow P, Rappaport R. Greater susceptibility to hypothalamo pituitary irradiation in younger children with acute lymphoblastic leukemia. J Pediatr. 1986;108(2):332.PubMedGoogle Scholar
  25. 25.
    Brauner R, Adan L, Souberbielle JC, Esperou H, Michon J, Devergie A, et al. Contribution of growth hormone deficiency to the growth failure that follows bone marrow transplantation. J Pediatr. 1997;130(5):785–92.PubMedGoogle Scholar
  26. 26.
    Chemaitilly W, Sklar CA. Endocrine complications of hematopoietic stem cell transplantation. Endocrinol Metab ClinNorth Am. 2007;36(4):983–98.Google Scholar
  27. 27.
    Clement-de BA, Oostdijk W, Van Weel-Sipman MH, Van den Broeck J, Wit JM, Vossen JM. Final height and hormonal function after bone marrow transplantation in children. J Pediatr. 1996;129(4):544–50.Google Scholar
  28. 28.
    Chemaitilly W, Boulad F, Heller G, Kernan NA, Small TN, O’Reilly RJ, et al. Final height in pediatric patients after hyperfractionated total body irradiation and stem cell transplantation. Bone Marrow Transplant. 2007;40(1):29–35.PubMedGoogle Scholar
  29. 29.
    Couto-Silva AC, Trivin C, Esperou H, Michon J, Baruchel A, Lemaire P, et al. Final height and gonad function after total body irradiation during childhood. Bone Marrow Transplant. 2006;38(6):427–32.PubMedGoogle Scholar
  30. 30.
    Papadimitriou A, Urena M, Hamill G, Stanhope R, Leiper AD. Growth hormone treatment of growth failure secondary to total body irradiation and bone marrow transplantation. Arch Dis Child. 1991;66(6):689–92.PubMedPubMedCentralGoogle Scholar
  31. 31.
    Cohen A, Rovelli A, Bakker B, Uderzo C, van Lint MT, Esperou H, et al. Final height of patients who underwent bone marrow transplantation for hematological disorders during childhood: a study by the Working Party for Late Effects-EBMT. Blood. 1999;93(12):4109–15.PubMedGoogle Scholar
  32. 32.
    Clement SC, Schoot RA, Slater O, Chisholm JC, Abela C, Balm AJ, et al. Endocrine disorders among long-term survivors of childhood head and neck rhabdomyosarcoma. Eur J Cancer. 2015;54:1–10.PubMedGoogle Scholar
  33. 33.
    Punyko JA, Mertens AC, Gurney JG, Yasui Y, Donaldson SS, Rodeberg DA, et al. Long-term medical effects of childhood and adolescent rhabdomyosarcoma: a report from the childhood cancer survivor study. Pediatr Blood Cancer. 2005;44(7):643–53.PubMedGoogle Scholar
  34. 34.
    Cheuk DK, Billups CA, Martin MG, Roland CR, Ribeiro RC, Krasin MJ, et al. Prognostic factors and long-term outcomes of childhood nasopharyngeal carcinoma. Cancer. 2011;117(1):197–206.PubMedGoogle Scholar
  35. 35.
    Pomarede R, Czernichow P, Zucker JM, Schlienger P, Haye C, Rosenwald JC, et al. Incidence of anterior pituitary deficiency after radiotherapy at an early age: study in retinoblastoma. Acta Paediatr Scand. 1984;73(1):115–9.PubMedGoogle Scholar
  36. 36.
    Friedman DN, Sklar CA, Oeffinger KC, Kernan NA, Khakoo Y, Marr BP, et al. Long-term medical outcomes in survivors of extra-ocular retinoblastoma: the Memorial Sloan-Kettering Cancer Center (MSKCC) experience. Pediatr Blood Cancer. 2013;60(4):694–9.PubMedGoogle Scholar
  37. 37.
    Narayanan KR, Bansal D, Walia R, Sachdeva N, Bhansali A, Varma N, et al. Growth failure in children with chronic myeloid leukemia receiving imatinib is due to disruption of GH/IGF-1 axis. Pediatr Blood Cancer. 2013;60(7):1148–53.PubMedGoogle Scholar
  38. 38.
    Tauer JT, Hofbauer LC, Jung R, Gerdes S, Glauche I, Erben RG, et al. Impact of long-term exposure to the tyrosine kinase inhibitor imatinib on the skeleton of growing rats. PLoSOne. 2015;10(6):e0131192.Google Scholar
  39. 39.
    Growth Hormone Research Society. Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: summary statement of the GH Research Society. GH Research Society. J Clin Endocrinol Metab. 2000;85(11):3990–3.Google Scholar
  40. 40.
    Sklar CA, Antal Z, Chemaitilly W, Cohen LE, Follin C, Meacham LR, et al. Hypothalamic-pituitary and growth disorders in survivors of childhood cancer: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103:2761.PubMedGoogle Scholar
  41. 41.
    Geffner ME. The growth without growth hormone syndrome. Endocrinol Metab Clin North Am. 1996;25(3):649–63.PubMedGoogle Scholar
  42. 42.
    Hobbie WL, Mostoufi SM, Carlson CA, Gruccio D, Ginsberg JP. Prevalence of advanced bone age in a cohort of patients who received cis-retinoic acid for high-risk neuroblastoma. Pediatr Blood Cancer. 2011;56(3):474–6.PubMedGoogle Scholar
  43. 43.
    Clayton PE, Shalet SM. The evolution of spinal growth after irradiation. Clin Oncol (R Coll Radiol). 1991;3(4):220–2.Google Scholar
  44. 44.
    Tanner JM, Whitehouse RH, Hughes PC, Carter BS. Relative importance of growth hormone and sex steroids for the growth at puberty of trunk length, limb length, and muscle width in growth hormone-deficient children. J Pediatr. 1976;89(6):1000–8.PubMedGoogle Scholar
  45. 45.
    Marin G, Domene HM, Barnes KM, Blackwell BJ, Cassorla FG, Cutler GB Jr. The effects of estrogen priming and puberty on the growth hormone response to standardized treadmill exercise and arginine-insulin in normal girls and boys. J Clin Endocrinol Metab. 1994;79(2):537–41.PubMedGoogle Scholar
  46. 46.
    Meinhardt UJ, Ho KK. Modulation of growth hormone action by sex steroids. Clin Endocrinol (Oxf). 2006;65(4):413–22.Google Scholar
  47. 47.
    Sklar CA, Constine LS. Chronic neuroendocrinological sequelae of radiation therapy. Int J Radiat Oncol Biol Phys. 1995;31(5):1113–21.PubMedGoogle Scholar
  48. 48.
    Sklar C, Sarafoglou K, Whittam E. Efficacy of insulin-like growth factor binding protein 3 in predicting the growth hormone response to provocative testing in children treated with cranial irradiation. Acta Endocrinol (Copenh). 1993;129(6):511–5.Google Scholar
  49. 49.
    Weinzimer SA, Homan SA, Ferry RJ, Moshang T. Serum IGF-I and IGFBP-3 concentrations do not accurately predict growth hormone deficiency in children with brain tumours. Clin Endocrinol (Oxf). 1999;51(3):339–45.Google Scholar
  50. 50.
    Sfeir JG, Kittah NE, Tamhane SU, Jasim S, Chemaitilly W, Cohen L, et al. Diagnosis of growth hormone deficiency as a late effect of radiotherapy in survivors of childhood cancers. J Clin Endocrinol Metab. 2018;103:2785–93.PubMedGoogle Scholar
  51. 51.
    Ham JN, Ginsberg JP, Hendell CD, Moshang T Jr. Growth hormone releasing hormone plus arginine stimulation testing in young adults treated in childhood with cranio-spinal radiation therapy. Clin Endocrinol (Oxf). 2005;62(5):628–32.Google Scholar
  52. 52.
    Darzy KH, Aimaretti G, Wieringa G, Gattamaneni HR, Ghigo E, Shalet SM. The usefulness of the combined growth hormone (GH)-releasing hormone and arginine stimulation test in the diagnosis of radiation-induced GH deficiency is dependent on the post-irradiation time interval. J Clin Endocrinol Metab. 2003;88(1):95–102.PubMedGoogle Scholar
  53. 53.
    Schriock EA, Lustig RH, Rosenthal SM, Kaplan SL, Grumbach MM. Effect of growth hormone (GH)-releasing hormone (GRH) on plasma GH in relation to magnitude and duration of GH deficiency in 26 children and adults with isolated GH deficiency or multiple pituitary hormone deficiencies: evidence for hypothalamic GRH deficiency. J Clin Endocrinol Metab. 1984;58(6):1043–9.PubMedGoogle Scholar
  54. 54.
    Constine LS, Woolf PD, Cann D, Mick G, McCormick K, Raubertas RF, et al. Hypothalamic-pituitary dysfunction after radiation for brain tumors. N Engl J Med. 1993;328(2):87–94.PubMedGoogle Scholar
  55. 55.
    Pyle SI, Waterhouse AM, Greulich WW. Attributes of the radiographic standard of reference for the National Health Examination Survey. Am J Phys Anthropol. 1971;35(3):331–7.PubMedGoogle Scholar
  56. 56.
    Grimberg A, DiVall SA, Polychronakos C, Allen DB, Cohen LE, Quintos JB, et al. Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency. Horm Res Paediatr. 2016;86(6):361–97.PubMedGoogle Scholar
  57. 57.
    Brownstein CM, Mertens AC, Mitby PA, Stovall M, Qin J, Heller G, et al. Factors that affect final height and change in height standard deviation scores in survivors of childhood cancer treated with growth hormone: a report from the childhood cancer survivor study. J Clin Endocrinol Metab. 2004;89(9):4422–7.PubMedGoogle Scholar
  58. 58.
    Ciaccio M, Gil S, Guercio G, Vaiani E, Alderete D, Palladino M, et al. Effectiveness of rhGH treatment on adult height in GH-deficient childhood survivors of medulloblastoma. Horm Res Paediatr. 2010;73(4):281–6.PubMedGoogle Scholar
  59. 59.
    Beckers D, Thomas M, Jamart J, Francois I, Maes M, Lebrethon MC, et al. Adult final height after GH therapy for irradiation-induced GH deficiency in childhood survivors of brain tumors: the Belgian experience. Eur J Endocrinol. 2010;162(3):483–90.PubMedGoogle Scholar
  60. 60.
    Chemaitilly W, Merchant TE, Li Z, Barnes N, Armstrong GT, Ness KK, et al. Central precocious puberty following the diagnosis and treatment of paediatric cancer and central nervous system tumours: presentation and long-term outcomes. Clin Endocrinol (Oxf). 2015;84:361–71.Google Scholar
  61. 61.
    Chemaitilly W, Robison LL. Safety of growth hormone treatment in patients previously treated for cancer. Endocrinol Metab Clin North Am. 2012;41(4):785–92.PubMedGoogle Scholar
  62. 62.
    Raman S, Grimberg A, Waguespack SG, Miller BS, Sklar CA, Meacham LR, et al. Risk of Neoplasia in Pediatric Patients Receiving Growth Hormone Therapy - A report from the Pediatric Endocrine Society Drug and Therapeutics Committee. J Clin Endocrinol Metab. 2015;100:2192–203:jc20151002.PubMedPubMedCentralGoogle Scholar
  63. 63.
    Ergun-Longmire B, Mertens AC, Mitby P, Qin J, Heller G, Shi W, et al. Growth hormone treatment and risk of second neoplasms in the childhood cancer survivor. J Clin Endocrinol Metab. 2006;91(9):3494–8.PubMedGoogle Scholar
  64. 64.
    Sklar CA, Mertens AC, Mitby P, Occhiogrosso G, Qin J, Heller G, et al. Risk of disease recurrence and second neoplasms in survivors of childhood cancer treated with growth hormone: a report from the childhood cancer survivor study. J Clin Endocrinol Metab. 2002;87(7):3136–41.PubMedGoogle Scholar
  65. 65.
    Tamhane S, Sfeir JG, Kittah NEN, Jasim S, Chemaitilly W, Cohen LE, et al. Growth hormone therapy in childhood cancer survivors: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2018;103:2794–801.PubMedGoogle Scholar
  66. 66.
    Mackenzie S, Craven T, Gattamaneni HR, Swindell R, Shalet SM, Brabant G. Long-term safety of growth hormone replacement after CNS irradiation. J Clin Endocrinol Metab. 2011;96(9):2756–61.PubMedGoogle Scholar
  67. 67.
    Patterson BC, Chen Y, Sklar CA, Neglia J, Yasui Y, Mertens A, et al. Growth hormone exposure as a risk factor for the development of subsequent neoplasms of the central nervous system: a report from the childhood cancer survivor study. J Clin Endocrinol Metab. 2014;99(6):2030–7.PubMedPubMedCentralGoogle Scholar
  68. 68.
    Elbornsson M, Gotherstrom G, Bosaeus I, Bengtsson BA, Johannsson G, Svensson J. Fifteen years of GH replacement increases bone mineral density in hypopituitary patients with adult-onset GH deficiency. Eur J Endocrinol. 2012;166(5):787–95.PubMedPubMedCentralGoogle Scholar
  69. 69.
    Elbornsson M, Gotherstrom G, Bosaeus I, Bengtsson BA, Johannsson G, Svensson J. Fifteen years of GH replacement improves body composition and cardiovascular risk factors. Eur J Endocrinol. 2013;168(5):745–53.PubMedPubMedCentralGoogle Scholar
  70. 70.
    Chemaitilly W, Trivin C, Adan L, Gall V, Sainte-Rose C, Brauner R. Central precocious puberty: clinical and laboratory features. Clin Endocrinol (Oxf). 2001;54(3):289–94.Google Scholar
  71. 71.
    Carel JC, Leger J. Clinical practice. Precocious puberty. N Engl J Med. 2008;358(22):2366–77.PubMedGoogle Scholar
  72. 72.
    Gan HW, Phipps K, Aquilina K, Gaze MN, Hayward R, Spoudeas HA. Neuroendocrine morbidity after pediatric optic gliomas: a longitudinal analysis of 166 children over 30 years. J Clin Endocrinol Metab. 2015;100(10):3787–99.PubMedGoogle Scholar
  73. 73.
    Trivin C, Couto-Silva AC, Sainte-Rose C, Chemaitilly W, Kalifa C, Doz F, et al. Presentation and evolution of organic central precocious puberty according to the type of CNS lesion. Clin Endocrinol (Oxf). 2006;65(2):239–45.Google Scholar
  74. 74.
    Oberfield SE, Soranno D, Nirenberg A, Heller G, Allen JC, David R, et al. Age at onset of puberty following high-dose central nervous system radiation therapy. Arch Pediatr Adolesc Med. 1996;150(6):589–92.PubMedGoogle Scholar
  75. 75.
    Armstrong GT, Whitton JA, Gajjar A, Kun LE, Chow EJ, Stovall M, et al. Abnormal timing of menarche in survivors of central nervous system tumors: a report from the childhood cancer survivor study. Cancer. 2009;115(11):2562–70.PubMedPubMedCentralGoogle Scholar
  76. 76.
    Carel JC, Eugster EA, Rogol A, Ghizzoni L, Palmert MR, Antoniazzi F, et al. Consensus statement on the use of gonadotropin-releasing hormone analogs in children. Pediatrics. 2009;123(4):e752–e62.PubMedGoogle Scholar
  77. 77.
    Sklar CA, Robison LL, Nesbit ME, Sather HN, Meadows AT, Ortega JA, et al. Effects of radiation on testicular function in long-term survivors of childhood acute lymphoblastic leukemia: a report from the Children Cancer Study Group. J Clin Oncol. 1990;8(12):1981–7.PubMedGoogle Scholar
  78. 78.
    Siimes MA, Rautonen J. Small testicles with impaired production of sperm in adult male survivors of childhood malignancies. Cancer. 1990;65(6):1303–6.PubMedGoogle Scholar
  79. 79.
    Ishiguro H, Yasuda Y, Tomita Y, Shinagawa T, Shimizu T, Morimoto T, et al. Gonadal shielding to irradiation is effective in protecting testicular growth and function in long-term survivors of bone marrow transplantation during childhood or adolescence. Bone Marrow Transplant. 2007;39(8):483–90.PubMedGoogle Scholar
  80. 80.
    Brignardello E, Felicetti F, Castiglione A, Nervo A, Biasin E, Ciccone G, et al. Gonadal status in long-term male survivors of childhood cancer. J Cancer Res Clin Oncol. 2016;142(5):1127–32.PubMedGoogle Scholar
  81. 81.
    Palmert MR, Dunkel L. Clinical practice. Delayed puberty. N Engl J Med. 2012;366(5):443–53.PubMedGoogle Scholar
  82. 82.
    Boehm U, Bouloux PM, Dattani MT, de Roux N, Dode C, Dunkel L, et al. Expert consensus document: European Consensus Statement on congenital hypogonadotropic hypogonadism--pathogenesis, diagnosis and treatment. Nat Rev Endocrinol. 2015;11(9):547–64.PubMedGoogle Scholar
  83. 83.
    Fleseriu M, Hashim IA, Karavitaki N, Melmed S, Murad MH, Salvatori R, et al. Hormonal replacement in hypopituitarism in adults: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2016;101(11):3888–921.PubMedGoogle Scholar
  84. 84.
    Metzger ML, Meacham LR, Patterson B, Casillas JS, Constine LS, Hijiya N, et al. Female reproductive health after childhood, adolescent, and young adult cancers: guidelines for the assessment and management of female reproductive complications. J Clin Oncol. 2013;31(9):1239–47.PubMedPubMedCentralGoogle Scholar
  85. 85.
    Kenney LB, Cohen LE, Shnorhavorian M, Metzger ML, Lockart B, Hijiya N, et al. Male reproductive health after childhood, adolescent, and young adult cancers: a report from the Children’s Oncology Group. J Clin Oncol. 2012;30(27):3408–16.PubMedPubMedCentralGoogle Scholar
  86. 86.
    Moskowitz CS, Chou JF, Sklar CA, Barnea D, Ronckers CM, Friedman DN, et al. Radiation-associated breast cancer and gonadal hormone exposure: a report from the childhood cancer survivor study. Br J Cancer. 2017;117:290.PubMedPubMedCentralGoogle Scholar
  87. 87.
    Chemaitilly W, Li Z, Krasin MJ, Brooke RJ, Wilson CL, Green DM, et al. Premature ovarian insufficiency in childhood cancer survivors: a report from the St. Jude Lifetime Cohort. J Clin Endocrinol Metab. 2017;102:2242–50.PubMedPubMedCentralGoogle Scholar
  88. 88.
    Rose SR, Lustig RH, Pitukcheewanont P, Broome DC, Burghen GA, Li H, et al. Diagnosis of hidden central hypothyroidism in survivors of childhood cancer. J Clin Endocrinol Metab. 1999;84(12):4472–9.PubMedGoogle Scholar
  89. 89.
    Darzy KH, Shalet SM. Circadian and stimulated thyrotropin secretion in cranially irradiated adult cancer survivors. J Clin Endocrinol Metab. 2005;90(12):6490–7.PubMedGoogle Scholar
  90. 90.
    Shalitin S, Laur E, Lebenthal Y, Ash S, Yaniv I, Phillip M. Endocrine complications and components of the metabolic syndrome in survivors of childhood malignant non-brain solid tumors. Horm Res Paediatr. 2014;81(1):32–42.PubMedGoogle Scholar
  91. 91.
    Follin C, Erfurth EM. Long-term effect of cranial radiotherapy on pituitary-hypothalamus area in childhood acute lymphoblastic leukemia survivors. Curr Treat Options Oncol. 2016;17(9):50.PubMedPubMedCentralGoogle Scholar
  92. 92.
    Sanders JE, Pritchard S, Mahoney P, Amos D, Buckner CD, Witherspoon RP, et al. Growth and development following marrow transplantation for leukemia. Blood. 1986;68(5):1129–35.PubMedGoogle Scholar
  93. 93.
    Patterson BC, Truxillo L, Wasilewski-Masker K, Mertens AC, Meacham LR. Adrenal function testing in pediatric cancer survivors. Pediatr Blood Cancer. 2009;53(7):1302–7.PubMedGoogle Scholar
  94. 94.
    Tritos NA, Klibanski A. Hyperprolactinemia. JAMA. 2015;314(16):1742–3.PubMedGoogle Scholar
  95. 95.
    Balachandar S, Dunkel IJ, Khakoo Y, Wolden S, Allen J, Sklar CA. Ovarian function in survivors of childhood medulloblastoma: impact of reduced dose craniospinal irradiation and high-dose chemotherapy with autologous stem cell rescue. Pediatr Blood Cancer. 2015;62:317–21.PubMedGoogle Scholar
  96. 96.
    Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(2):273–88.PubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Division of EndocrinologySt. Jude Children’s Research HospitalMemphisUSA

Personalised recommendations